738
M. Dohlus et al.
MEVION S250
IBA Proteus ONE
(with courtesy of IBA SA)
Varian ProBeam
Fig. 11.31 Single-room facilities commercialized by MEVION, IBA, and Varian
followed by short magnetic channels and accelerators which rotate around the
patient.
A very high field 15-tons niobium-tin superconducting 250 MeV synchrocyclotron was developed by Mevion Medical Systems Inc. in collaboration with
the Massachusetts Institute of Technology (MIT) and the Massachusetts Medical
Hospital. Mevion S250 is the firstly constructed system based on the concept
of single-room facility which treated the first patient in December 2013. The
accelerator is mounted directly on the 190 ◦ isocentric gantry (Fig. 11.31a) with a
superconductive coils producing a 8.7 T central magnetic field. The first version of
the system which featured a passive beam delivery system has been updated to a
‘pencil beam’ system for active scanning.
The Proteus ONE system of IBA consists of a compact 230 MeV superconducting synchrocyclotron, named S2C2. The energy selection system is mounted on the
220 ◦ isocentric gantry (Fig. 11.31b). In September 2016 the Lacassagne Centre in
Nice treated the first patient with S2C2 accelerator.
The single-room system ProBeam of Varian system combines a 250 MeV
cyclotron—the first commercial superconductive accelerator developed for proton
therapy used at PSI since 2007—and the 360 ◦ gantry (Fig. 11.31c).
M. Dohlus et al.
MEVION S250
IBA Proteus ONE
(with courtesy of IBA SA)
Varian ProBeam
Fig. 11.31 Single-room facilities commercialized by MEVION, IBA, and Varian
followed by short magnetic channels and accelerators which rotate around the
patient.
A very high field 15-tons niobium-tin superconducting 250 MeV synchrocyclotron was developed by Mevion Medical Systems Inc. in collaboration with
the Massachusetts Institute of Technology (MIT) and the Massachusetts Medical
Hospital. Mevion S250 is the firstly constructed system based on the concept
of single-room facility which treated the first patient in December 2013. The
accelerator is mounted directly on the 190 ◦ isocentric gantry (Fig. 11.31a) with a
superconductive coils producing a 8.7 T central magnetic field. The first version of
the system which featured a passive beam delivery system has been updated to a
‘pencil beam’ system for active scanning.
The Proteus ONE system of IBA consists of a compact 230 MeV superconducting synchrocyclotron, named S2C2. The energy selection system is mounted on the
220 ◦ isocentric gantry (Fig. 11.31b). In September 2016 the Lacassagne Centre in
Nice treated the first patient with S2C2 accelerator.
The single-room system ProBeam of Varian system combines a 250 MeV
cyclotron—the first commercial superconductive accelerator developed for proton
therapy used at PSI since 2007—and the 360 ◦ gantry (Fig. 11.31c).